Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer Meeting Abstract
| Authors: | Moreno-Aspitia, A.; Holmes, E. M.; Jackisch, C.; de Azambuja, E.; Boyle, F. M.; Hillman, D. W.; Korde, L. A.; Fumagalli, D.; Izquierdo, M. A.; McCullough, A. E.; Wolff, A. C.; Pritchard, K. I.; Untch, M.; Lang, I.; Xu, B.; Smith, I. E.; Barrios, C. H.; Gelber, R. D.; Baselga, J.; Piccart-Gebhart, M. J. |
| Abstract Title: | Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 9s |
| Language: | English |
| ACCESSION: | WOS:000411895700020 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.502 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 502 -- Source: Wos |
